Current species’ range displacements are mostly triggered by climate change but European landscapes are largely dominated by human activities. In this study we identify the most promising spatial adaptive trajectories (SATs) for the thirty most threatened non volant mammal species in Europe up to 2080 (under three climate and land change scenarios) and where/when SATs of each species synchronically converge. We found large contrasts on the persistence of species in SATs, with some species largely reliant on the functionality of areas where many SATs converge. Overall, SATs and convergence centers are not adequately covered by existing conservation areas and coincide with crop and arable lands, compromising species persistence. It is important to invest in the protection of SATs and convergence centers through a mix of conventional instruments and new collaborative forms with the socio-economy. Anticipative plans at long-term coupled with risk analysis offer decision–makers templates to prevent negative surprises.

Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by progressive accumulation of a rare population of CD5+ B lymphocytes in peripheral blood, bone marrow and lymphoid tissues. CLL exhibits remarkable clinical heterogeneity, with some patients presenting with indolent disease and others progressing rapidly to aggressive CLL. The significant heterogeneity of CLL underscores the importance of identifying novel prognostic markers. Recently, the RAS-related gene RRAS2 has emerged as both a driver oncogene and a potential marker for CLL progression, with higher RRAS2 expression associated with poorer disease prognosis. Although missense somatic mutations in the coding sequence of RRAS2 have not been described in CLL, this study reports the frequent detection of three somatic mutations in the 3' untranslated region (3'UTR) affecting positions +26, +53, and +180 downstream of the stop codon in the mRNA. An inverse relationship was observed between these three somatic mutations and RRAS2 mRNA expression, which correlated with lower blood lymphocytosis and better prognosis. These findings highlight the importance of RRAS2 overexpression in CLL development and prognosis and point to somatic mutations in its 3'UTR as novel mechanistic clues. Our results may contribute to the development of targeted therapeutic strategies and improved risk stratification for CLL patients.